Tag Archives: treatment of patients with SAA

Novartis: US FDA grants Breakthrough Therapy designation to Promacta® (eltrombopag) for the treatment of patients with SAA

Posted on 9, January 2018 by

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is the only TPO receptor agonist indicated for the treatment of patients … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Science, Switzerland

Tagged , , , ,